Suzhou Ribo Life Science Co (06938.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 11.27B

MomentumView details →

1D Return

+2.80%

YTD Return

—

RSI (14)

69.4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 11.27B

RSI (14)

69.4

MomentumView details →

1D Return

+2.80%

YTD Return

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

HKD 0.02

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Next earningsMar 25, 2027 →

Latest newsMore news →

Ribo and Madrigal achieved the first candidate drug nomination milestone in their siRNA partnership for MASH therapies.65d ago

Similar companies

欧林生物688319.SH Bio-Techne CorporationTECH Mabwell-b02493.HK 诺唯赞688105.SH HBM Holdings Limited02142.HK Axsome Therapeutics, Inc.AXSM Find similar companies →

Latest newsMore news →

Ribo and Madrigal achieved the first candidate drug nomination milestone in their siRNA partnership for MASH therapies.65d ago